Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Core Viewpoint - Wave Life Sciences Ltd. has initiated a public offering of $250 million in ordinary shares and pre-funded warrants, with an option for underwriters to purchase an additional 15% of the total offering [1][2]. Company Overview - Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines aimed at transforming human health. The company utilizes its PRISM® platform, which integrates various modalities and innovations in chemistry to develop treatments for both rare and common disorders [5]. - The company's pipeline includes clinical programs targeting obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington's disease, along with several preclinical programs leveraging its RNA therapeutics toolkit [5]. Offering Details - The public offering will be conducted by Jefferies, Leerink Partners, and BofA Securities as joint book-running managers [2]. - The offering is subject to market conditions, and there is no guarantee regarding its completion or the final terms [2]. - A prospectus and related supplement will be filed with the SEC, detailing the terms of the offering [3].